Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis

NCT00625326 is registered in ClinicalTrials.gov with Deltanoid Pharmaceuticals as lead sponsor.

NCT NCT00625326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00625326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis
Lead sponsor
Deltanoid Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
June 30, 2009
Enrollment
321 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

plaque-type psoriasis